Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 8/20 | 0.45 |
| ▸ | SSTR5 | P35346 | 5/20 | 0.42 |
| ▸ | RET | P07949 | 1/20 | 0.42 |
| ▸ | SMYD3 | Q9H7B4 | 3/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20068967 | 0.86 | ATM (0.44) | ACKR3SSTR5RETSMYD3ATM | |
| SCHEMBL20147650 | 0.82 | SMYD3 (0.44) | ACKR3SSTR5RETSMYD3ATM | |
| SCHEMBL20147988 | 0.80 | THRB (0.49) | RET | |
| SCHEMBL21652026 | 0.76 | MCHR1 (0.45) | RETMCHR1 | |
| SCHEMBL25504103 | 0.76 | RET (0.43) | RET | |
| SCHEMBL22857024 | 0.75 | RET (0.42) | ACKR3RETSMYD3MCHR1 | |
| SCHEMBL25504246 | 0.74 | RET (0.43) | ACKR3RETSMYD3 | |
| SCHEMBL21652021 | 0.74 | HSD11B1 (0.46) | MCHR1 | |
| SCHEMBL21652014 | 0.73 | CHRM1 (0.52) | RETMCHR1 | |
| SCHEMBL21652027 | 0.72 | NPC1 (0.53) | MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11648243-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2023-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11648243-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | ACKR3 1015/4885SSTR5 2822/4885RET 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.